Connect your AI

Wave Life Sciences WVE Accounts Receivable

Accounts Receivable at other companies

Eli LillyLLY

$18.43B+53.1%

Sarepta Therapeutics, Inc.SRPT

$394.82M-40.1%

Madrigal Pharmaceuticals, Inc.MDGL

$187.36M+205%

ALN

Alnylam PharmaceuticalsALNY

$883.96M+111%

Zevra Therapeutics, Inc.ZVRA

$22.1M+75.1%

PTC TherapeuticsPTCT

$219.92M+4.5%

Other financials

Income statement

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Profitability

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Wave Life Sciences's accounts receivable?: Wave Life Sciences (WVE) reported accounts receivable of $0 in Q1 2026.
How has Wave Life Sciences's accounts receivable changed year-over-year?: Wave Life Sciences's accounts receivable increased by 100.0% year-over-year, from -$1.42M to $0.
What is the long-term trend for Wave Life Sciences's accounts receivable?: Over 4 years (2020 to 2025), Wave Life Sciences's accounts receivable has grown at a -54.6% compound annual growth rate (CAGR), from $30M to $1.28M.
What does accounts receivable mean?: Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.